Cerus (NASDAQ:CERS) CEO William Mariner Greenman Sells 78,187 Shares of Stock

Cerus Corporation (NASDAQ:CERS) CEO William Mariner Greenman sold 78,187 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $2.01, for a total transaction of $157,155.87. Following the completion of the transaction, the chief executive officer owned 5,446,250 shares in the company, valued at $10,946,962.50. This trade represents a 1.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Cerus Stock Performance

CERS opened at $1.93 on Tuesday. The company’s 50 day moving average is $2.31 and its 200 day moving average is $1.86. The company has a current ratio of 1.73, a quick ratio of 1.17 and a debt-to-equity ratio of 0.62. The company has a market cap of $370.89 million, a price-to-earnings ratio of -24.13 and a beta of 1.51. Cerus Corporation has a 12-month low of $1.12 and a 12-month high of $2.96.

Cerus (NASDAQ:CERS) last announced its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. The business had revenue of $64.58 million during the quarter, compared to analysts’ expectations of $59.31 million. On average, equities research analysts predict that Cerus Corporation will post -0.08 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CERS. Wall Street Zen cut Cerus from a “buy” rating to a “hold” rating in a report on Saturday. TD Cowen reissued a “buy” rating on shares of Cerus in a report on Monday, January 12th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Key Stories Impacting Cerus

Here are the key news stories impacting Cerus this week:

• Neutral Sentiment: Short-interest data flagged an apparent increase for the March 9 reporting period but shows 0 shares and reports a days-to-cover of 0.0 — the print looks incorrect or incomplete and should be treated as unreliable until exchanges update filings.
• Neutral Sentiment: Analysts overview: The Globe and Mail ran a piece discussing analysts’ views on Cerus alongside peers (Fennec). That coverage provides context but does not appear to contain new company-specific catalysts. Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Fennec Pharmaceuticals (FENC)
• Negative Sentiment: Insider selling: several insiders disclosed sales between Mar. 5–9 that reduce insider ownership by low-single-digit to mid-single-digit percentages. Notable filings: CEO William Mariner Greenman sold 78,187 shares (~$157k). COO Vivek Jayaraman sold 34,094 shares (~$68.5k). CFO Kevin D. Green sold 27,796 shares (~$55.9k). Director Richard J. Benjamin reported multiple sales (61,233; 40,426; 24,235 shares) at ~$2.06–$1.88 across Mar. 5–9. Insider Chrystal Jensen sold 30,845 shares (~$62k). Collectively, these are meaningful in signaling added supply and may weigh on sentiment even if sales were for personal/liquidity reasons. CEO filing: http://www.sec.gov/Archives/edgar/data/1020214/000137725826000004/xslF345X05/ownership.xml COO filing: http://www.sec.gov/Archives/edgar/data/1020214/000160545626000004/xslF345X05/ownership.xml Chrystal Jensen filing: http://www.sec.gov/Archives/edgar/data/1020214/000156425226000004/xslF345X05/ownership.xml Richard Benjamin filings: http://www.sec.gov/Archives/edgar/data/1020214/000129632226000004/xslF345X05/ownership.xml CFO filing: http://www.sec.gov/Archives/edgar/data/1020214/000145935126000005/xslF345X05/ownership.xml

Hedge Funds Weigh In On Cerus

Several large investors have recently added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new stake in shares of Cerus in the fourth quarter worth $25,000. CIBC Bancorp USA Inc. bought a new stake in shares of Cerus during the 3rd quarter valued at $31,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Cerus during the 1st quarter valued at $32,000. Aquatic Capital Management LLC purchased a new position in shares of Cerus during the 3rd quarter valued at $35,000. Finally, MML Investors Services LLC bought a new position in Cerus in the 4th quarter worth $37,000. Hedge funds and other institutional investors own 78.37% of the company’s stock.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.